Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer
Yohei Kubota, Kohei Shitara
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 12

Showing 12 citing articles:

Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application
Rui Zheng, Xiaobin Liu, Yufu Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 6
Claudin 18.2: An attractive marker in pancreatic ductal adenocarcinoma
Anna Maria Valentini, Graziana Arborea, Ilaria Grassi, et al.
Oncology Letters (2025) Vol. 29, Iss. 3
Open Access
Claudin 18.2 Expression in 1,404 Digestive Tract Adenocarcinomas including 1,175 Colorectal Carcinomas: Distinct Colorectal Carcinoma Subtypes are Claudin 18.2 Positive
Kelsey McHugh, Rish K. Pai, Robert C. Grant, et al.
Modern Pathology (2025) Vol. 38, Iss. 5, pp. 100712-100712
Open Access
Evaluating the pharmacokinetics of zolbetuximab in gastric adenocarcinoma
Jane E. Rogers, Michael Leung, Jaffer A. Ajani
Expert Opinion on Drug Metabolism & Toxicology (2025)
Closed Access
Advancements in the conservation of the conformational epitope of membrane protein immunogens
Aisha Mahboob, Nishat Fatma, Faraz Ahmed, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Extent and clinical significance of the therapy-relevant tight junction protein Claudin 18.2 in pancreatic ductal adenocarcinoma - real-world evidence
Su Ir Lyu, Caroline Fretter, Adrian Georg Simon, et al.
Translational Oncology (2024) Vol. 47, pp. 102044-102044
Open Access | Times Cited: 4
Zolbetuximab: First Approval
Susan J. Keam
Drugs (2024) Vol. 84, Iss. 8, pp. 977-983
Closed Access | Times Cited: 3
Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins
Amberley D. Stephens, Trevor Wilkinson
BioDrugs (2024) Vol. 38, Iss. 6, pp. 769-794
Open Access | Times Cited: 3
Biomarker-oriented chemo-immunotherapy for advanced gastric cancer
Koji Kono, Shotaro Nakajima, Kosaku Mimura
International Journal of Clinical Oncology (2024) Vol. 29, Iss. 7, pp. 865-872
Closed Access | Times Cited: 2
Protein isoform-centric therapeutics: expanding targets and increasing specificity
Peter Kjer-Hansen, Tri Giang Phan, Robert J. Weatheritt
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 10, pp. 759-779
Closed Access | Times Cited: 2
The Role of CLDN18.2 in Gastric Cancer Prognosis: A Systematic Review and Meta-Analysis
Francisco Cézar Aquino de Moraes, Luis Eduardo Rodrigues Sobreira, Maria Eduarda Cavalcanti Souza, et al.
Biomarkers (2024), pp. 1-14
Closed Access | Times Cited: 2
Zolbetuximab for Unresectable and Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Literature
A. Samanta, Arindam Ghosh, Monalisa Sarma
Cureus (2024)
Open Access
Page 1

Scroll to top